Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders Academic Article Article uri icon


MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • Esophageal Neoplasms
  • Esophagogastric Junction
  • Niacinamide
  • Phenylurea Compounds
  • Stomach Neoplasms


  • Little is known whether cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) can predict both memory decline and associated longitudinal medial temporal lobe (MTL) gray matter (GM) reductions in cognitively healthy individuals. Fifty-seven normal elderly subjects received comprehensive evaluation at baseline and 2 years later. The baseline phosphorylated tau 231 (p-tau 231), total tau, the amyloid beta (Aβ) Aβ42/Aβ40, t-tau/Aβ42 and p-tau 231/Aβ42 ratios were examined as predictors of memory change and reductions in the global and MTL GM, determined from T1-weighted MRI. Twenty out of 57 participants experienced reduced memory performance at follow-up. The group with decreased memory performance showed higher baseline p-tau 231 (Z=-2.2, p=0.03), lower Aβ42/Aβ40 (t=-2.2 [55], p=0.04) and greater longitudinal MTL GM reductions (t [52]=-2.70, p=0.01). Higher baseline p-tau 231 was also associated with the absolute decrease in memory scores (rho=-0.30, p=0.02) and with longitudinal MTL GM reduction (F [2,52]=4.4, p=0.04, age corrected). Our results indicate that in normal individuals, elevated p-tau 231, a marker of neurofibrillary pathology is related to both a decrease in declarative memory and progressive atrophy of the MTL, suggesting its diagnostic potential in preclinical stage. © 2010 Elsevier Inc.

publication date

  • December 2011



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1016/j.neurobiolaging.2009.12.026

PubMed ID

  • 20133017

Additional Document Info

start page

  • 2131

end page

  • 2141


  • 32


  • 12